PatchMD Releases Medical Weight Loss Resources with Expert-Reviewed Articles on GLP-1 Agonists
14 juin 2024 09h00 HE
|
PatchMD
Las Vegas, NV, June 14, 2024 (GLOBE NEWSWIRE) -- PatchMD, a leader in innovative vitamin supplement delivery, is excited to announce the release of a series of comprehensive resources designed to...
North America Weight Loss Supplement Market Size, Share & Trends Analysis Report 2024-2030
14 juin 2024 07h07 HE
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "North America Weight Loss Supplement Market Size, Share & Trends Analysis Report by Type (Liquid, Pills), Ingredient (Vitamins & Minerals,...
Noom Announces Strategic Expansion of Executive Team with Key Leadership Appointments
13 juin 2024 12h14 HE
|
Noom Inc
Noom, the leading digital healthcare company, announces the appointment of three distinguished executives to its leadership team.
Noom Launches Noom Vibe, a Wellness Community and Habit Tracker Built for the Age of GLP-1s
03 juin 2024 08h04 HE
|
Noom Inc
Noom Launches Noom Vibe, a New Free Wellness Community App
United States Weight Loss Market Status & Forecast Report 2024: $90 Billion Industry Growth Driven by Explosive Sales of GLP-1 Prescription Drugs
31 mai 2024 04h47 HE
|
Research and Markets
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "The U.S. Weight Loss Market: 2024 Status Report & Forecast" report from Marketdata LLC has been added to ResearchAndMarkets.com's offering.The U.S....
UMeWorld Limited Invites Investors to Upcoming Webinar, June 4th at 12PM EST Hosted by CEO Michael Lee to Discuss the Upcoming Acquisition and Relocation
23 mai 2024 08h00 HE
|
UMeWorld Limited
UMeWorld Limited Invites Investors to Upcoming Webinar
UMeWorld Announces Strategic Expansion in the U.S. and Forecasts Significant Revenue Growth
16 mai 2024 08h00 HE
|
UMeWorld Limited
HONG KONG, May 16, 2024 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTCPK: UMEWF) is pleased to announce a strategic plan for expansion in the United States. Having secured proprietary enzymatic...
Reddit's Analysis on the Efficacy of FDA Approved Leading Weight Loss Drugs, Q4 2023 - Q2 2024: Focus on Semaglutide, Naltrexone-bupropion, Tirzepatide, Phentermine-topiramate, Liraglutide, Hydrogel
14 mai 2024 10h43 HE
|
Research and Markets
Dublin, May 14, 2024 (GLOBE NEWSWIRE) -- The "Reddit's Analysis on the Efficacy of Leading Weight Loss Drugs" report has been added to ResearchAndMarkets.com's offering.This comprehensive...
Will your health insurance cover weight-loss medications? It depends on several factors, including where you live
08 mai 2024 11h23 HE
|
medicareresources.org
Minneapolis, MN, May 08, 2024 (GLOBE NEWSWIRE) -- Interest in medications prescribed for weight loss is skyrocketing, sparking consumer questions about whether health insurance covers these...
Weight Loss/Weight Management (Obesity) Pipeline Insight, 2024: Drugs Under Development, Unmet Needs, Key Players, Collaborations, Licensing Agreement and Financing Details
08 mai 2024 05h39 HE
|
Research and Markets
Dublin, May 08, 2024 (GLOBE NEWSWIRE) -- The "Weight Loss/Weight Management (Obesity) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report...